Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: LAPATINIB
Sponsor: GlaxoSmithKline